These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 12448687)

  • 1. Hepatitis B virus resistance to lamivudine and its clinical implications.
    Liu X; Schinazi RF
    Antivir Chem Chemother; 2002 May; 13(3):143-55. PubMed ID: 12448687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
    Zhu Y; Curtis M; Borroto-Esoda K
    Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
    Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.
    Svicher V; Gori C; Trignetti M; Visca M; Micheli V; Bernassola M; Salpini R; Gubertini G; Longo R; Niero F; Ceccherini-Silberstein F; De Sanctis GM; Spanò A; Cappiello G; Perno CF
    J Hepatol; 2009 Mar; 50(3):461-70. PubMed ID: 19041149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.
    Ayres A; Bartholomeusz A; Lau G; Lam KC; Lee JY; Locarnini S
    J Clin Virol; 2003 May; 27(1):111-6. PubMed ID: 12727536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
    Delaney WE; Yang H; Westland CE; Das K; Arnold E; Gibbs CS; Miller MD; Xiong S
    J Virol; 2003 Nov; 77(21):11833-41. PubMed ID: 14557667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
    Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
    J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H.
    Fernández-Galindo DA; Sánchez-Ávila F; Bobadilla-Morales L; Gómez-Quiróz P; Bueno-Topete M; Armendáriz-Borunda J; Sánchez-Orozco LV
    J Med Virol; 2015 Jun; 87(6):985-92. PubMed ID: 25732900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
    Arslan U; Ural O; Findik D
    Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
    Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
    Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
    Liaw YF
    Antivir Chem Chemother; 2001; 12 Suppl 1():67-71. PubMed ID: 11594691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
    Santos EA; Sucupira MV; Arabe J; Gomes SA
    BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
    Ijaz S; Arnold C; Dervisevic S; Mechurova J; Tatman N; Tedder RS; Naoumov NV
    J Med Virol; 2008 Jul; 80(7):1160-70. PubMed ID: 18461609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.